Handelsavisen
prelaunch
Companies Healthcare 138610.KQ
13
138610.KQ KOSDAQ Biotechnology & Medical Research

Nibec Co Ltd

$22 900,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
14,4 %
ROE
10,1 %
Net margin
14,2 %
Debt / equity
0,22
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Nibec Co Ltd is a South Korean biotechnology company focused on pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of biopharmaceutical products.

Business. Nibec Co Ltd (138610.KQ) is a biotechnology and medical research company engaged in pharmaceuticals and medical research activities. The firm is listed on the KOSDAQ exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
10,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 138610.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 138610.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Nibec Co Ltd (138610.KQ) is a biotechnology and medical research company engaged in pharmaceuticals and medical research activities. The firm is listed on the KOSDAQ exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Nibec maintains a strong capital structure with a debt-to-equity ratio of 0.22, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 3.16, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's net cash position is negative after subtracting total debt, which introduces some liquidity risk.

    In terms of profitability, Nibec's return on equity (ROE) of 10.13% and return on assets (ROA) of 7.37% are strong indicators of efficient capital utilization and asset management. These metrics suggest the company is generating solid returns relative to its equity and total assets, which is favorable compared to the industry's typical performance benchmarks.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification could expose the company to higher operational and market risks if its primary market or product line experiences a downturn.

    Nibec's growth trajectory is supported by a positive operating cash flow of 5.82 billion KRW and a free cash flow of 2.79 billion KRW, indicating the company is generating sufficient cash to fund operations and potentially reinvest in growth opportunities. However, the company's capital expenditure of -5.27 billion KRW suggests a net reduction in capital spending, which may indicate a strategic shift or a focus on cost optimization.

    The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The risk assessment highlights the negative net cash position after subtracting total debt as a key flag, which could impact the company's ability to meet short-term obligations without external financing. The dilution risk is low, and no significant adjustments have been applied to the valuation metrics, suggesting the company's capital structure is stable.

    Recent events and disclosures indicate that Nibec's last actual EPS was -310.00 KRW, as reported in analyst estimates. This negative EPS suggests the company may be facing challenges in maintaining profitability, which could be a concern for investors and stakeholders.

    Key takeaways
    • Nibec maintains a strong capital structure with a low debt-to-equity ratio of 0.22.
    • The company's ROE of 10.13% and ROA of 7.37% indicate efficient capital and asset utilization.
    • Nibec's liquidity position is medium risk, with a current ratio of 3.16.
    • The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
    • Nibec's recent EPS of -310.00 KRW suggests potential challenges in maintaining profitability.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $22 900,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $45.82B
    Net cash
    -$10.00B
    Current ratio
    3.2
    Debt / equity
    0.2
    ROA
    7.4%
    ROE
    10.1%
    Cash conversion
    125.0%
    CapEx / revenue
    -16.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin14,4 %Above P75
    Net Margin14,2 %Above P75
    ROE10,1 %Above P75
    Capex / Rev-16,1 %Below median
    D/E0,22Bottom quartile
    Cash Conv1,25Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Nibec Co Ltd Market data — financials · 2026-05-26
    • Nibec Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    138610.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage